Pain Therapeutics (NASDAQ:PTIE) will be posting its quarterly earnings results before the market opens on Wednesday, October 18th. Analysts expect Pain Therapeutics to post earnings of ($0.55) per share for the quarter.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.17). On average, analysts expect Pain Therapeutics to post $-2.350 EPS for the current fiscal year and $-2.900 EPS for the next fiscal year.

Pain Therapeutics (NASDAQ:PTIE) opened at 4.829 on Wednesday. The firm has a 50 day moving average of $3.73 and a 200 day moving average of $4.23. The firm’s market capitalization is $31.85 million. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.

A number of research firms have recently commented on PTIE. Zacks Investment Research cut Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. Gabelli cut Pain Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 17th.

TRADEMARK VIOLATION NOTICE: “Pain Therapeutics (PTIE) Set to Announce Earnings on Wednesday” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.